Akzo's pharmaceutical sales rise in first half:
This article was originally published in Clinica
Executive Summary
In the first half of 1995, pharma revenues grew 5% at Dutch chemicals, fibres and pharma group Akzo Nobel. Pharma sales, which include Organon Teknika's diagnostics, increased to Fl 1,908 million ($1,066 million). Akzo attributed the growth to volume increases at Organon and its veterinary business. First-half group sales declined 3% to Fl 10,991 million, while net income improved to Fl 789 million compared with Fl 569 million in the previous year.
You may also be interested in...
Japan Grants Global-First Approval To Zolbetuximab, 15 Other New Drugs
Astellas's first-in class CLDN18.2-targeting antibody receives its first approval worldwide, while crovalimab and a number of drugs for rare diseases also receive nods from regulators and are now awaiting reimbursement price-listing.
Hanmi-OCI Merger Hits Wall As Brothers Win Shareholder Vote, Board Seats
The planned merger of Korea's Hanmi Pharm Group with OCI Group hits a major speed bump as the two sons of Hanmi's founder and other candidates recommended by them secture board seats. But it remains to be seen how the Lim brothers will fulfil their ambitious promises.
Beauty Firms Using AI-Based Tools Could Be Subject To Health Privacy Laws In US States
Using AI-based programs to collect and store consumer information risks running afoul of new health privacy laws cropping up in US states. Lack of federal regulation or guidance on the issue is one of the biggest challenges for beauty firms deploying AI, according to Stacy Marcus, partner at Reed Smith LLP.